Clinical Endpoints
Confidently control your trial’s evidence data.
Embrace a proven approach to endpoint management and protection without disrupting study timeline or goals.
The number of trial endpoints has increased year-over-year since 2003 and will continue to increase.
More endpoints, more opportunities. Influence a new standard for clinical data quality at a time when it’s so needed. Move the needle forward in a compliant, cost-efficient, and scientifically sound way to create real-world impact.
Simplify what feels complex
650+ scales supported and 6,000+ translations of those scales
Minimize data variability and errors
1.5 million-plus statistically aberrant signals detected with next-gen Study Analytics technology platform
Global reach, local support
Provide endpoints support for 50% of sites worldwide, with support for 100+ local languages
Explore our Clinical Endpoint solutions
Cognitive Assessments
Rater Training & Qualification
Independent Rating
Independent Review
Remote Assessments
Imaging Core Lab
Endpoint Adjudication Committees
Endpoint Protection
Endpoints & Assessments
Threat Detection
Study Insight Analytics
Electronic Assessments
eCOA/ePRO
Cutting-edge technology with the largest CNS eCOA plug-and-play library in the industry.
Neurostatus eEDSS
An enhanced digital version of the Neurostatus Expanded Disability Status Scale designed to improve a rater’s data entry experience. Developed in collaboration with Neurostatus UHB, a University Hospital Basel subsidiary and its CEO, Dr. Marcus D’Souza.
Seizure eDiary
Developed in partnership with participants, study teams, data managers and The Epilepsy Study Consortium (TESC), the eDiary was built with the participant and site experience in mind, and designed for speed, configurability and data integrity.
Our Clinical Endpoint technologies
The best way to predict the likelihood of your research study is to determine it
There’s no time for doubt or delays. WCG’s clinical endpoint solutions demystify trial efficacy by reducing clinical trial error rate and, subsequently, the risk of inconclusive and unsalvageable studies.
